ADOCIA Announces Half Year Report on Adocia’s Liquidity Agreement with Kepler Capital Markets
2024年7月20日 - 1:00AM
ビジネスワイヤ(英語)
Regulatory News:
Under the liquidity agreement entrusted by
ADOCIA (Paris:ADOC) to Kepler Capital Markets, the following
resources were listed on the liquidity account on June
30th 2024 :
- Number of shares : 10,329
- Cash balance of the liquidity account: € 208,460.92
During the 1st half of 2024, a total of:
Buy side
158,186 shares
€ 1,462,708.28
928 transactions
Sell side
150,404 shares
€ 1,421,855.74
935 transactions
The following resources appeared on the last half year statement
on December 31, 2023 on the liquidity account:
- Number of shares : 2,547
- Cash balance of the liquidity account: € 245,713.33
The following resources appeared on the liquidity account when
the activity started:
- Number of shares : 15,026
- Cash balance of the liquidity account: € 300,000.00
The liquidity agreement complies with AMF Decision n° 2021-01 of
June 22nd, 2021, renewing the implementation of liquidity contracts
for shares as an accepted market practice.
About Adocia
Adocia is a biotechnology company specializing in the discovery
and development of therapeutic solutions in the field of metabolic
diseases, primarily diabetes and obesity.
The company has a broad portfolio of drug candidates based on
four proprietary technology platforms: 1) The BioChaperone®
technology for the development of new generation insulins and
products combining different hormones; 2) AdOral®, an oral peptide
delivery technology; 3) AdoShell®, an immunoprotective biomaterial
for cell transplantation, with an initial application in pancreatic
cells transplantation; and 4) AdoGel®, a long-acting drug delivery
platform.
Adocia holds more than 25 patent families. Based in Lyon, the
company has about 80 employees. Adocia is listed on the regulated
market of Euronext™ Paris (Euronext: ADOC; ISIN: FR0011184241).
Disclaimer
This press release contains certain forward-looking statements
concerning Adocia and its business. Such forward-looking statements
are based on assumptions that Adocia considers as being reasonable.
However, there can be no guarantee that the estimates contained in
such forward-looking statements will be achieved, as such estimates
are subject to numerous risks including those set forth in the
“Risk Factors” section of the universal registration document that
was filed with the French Autorité des marchés financiers on April
29, 2024, available at www.adocia.com. Those risks include
uncertainties inherent in Adocia's short- or medium-term working
capital requirements, in research and development, future clinical
data, analyses and the evolution of economic conditions, the
financial markets and the markets in which Adocia operates, which
could impact the Company's short-term financing requirements and
its ability to raise additional funds.
The forward-looking statements contained in this press release
are also subject to risks not yet known to Adocia or not considered
as material by Adocia at this time. The occurrence of all or part
of such risks could cause the actual results, financial conditions,
performances, or achievements of Adocia be materially different
from those mentioned in the forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240719170092/en/
Adocia Olivier Soula CEO
contactinvestisseurs@adocia.com +33 (0)4 72 610 610
www.adocia.com
Ulysse Communication Adocia Press & Investor
Relations Bruno Arabian Nicolas Entz
adocia@ulysse-communication.com + 33 (0)6 87 88 47 26
Edoc Acquisition (NASDAQ:ADOC)
過去 株価チャート
から 7 2024 まで 8 2024
Edoc Acquisition (NASDAQ:ADOC)
過去 株価チャート
から 8 2023 まで 8 2024